前列腺癌(PCa)仍然是全球男性癌症相关死亡的主要原因之一。通常为处于危险中的男性提供多参数磁共振成像,如果可疑,有针对性的活检.然而,磁共振成像的假阴性率始终为18%;因此,人们对通过新技术提高成像诊断性能的兴趣日益浓厚。前列腺特异性膜抗原(PSMA)正电子发射断层扫描(PET)正在用于PCa分期,最近,用于前列腺内肿瘤定位。然而,已经观察到PSMAPET的执行方式和报告方式存在显著差异。
■在这篇评论中,我们的目的是评估这种变异性在调查PSMAPET在原发性PCa检查中的表现的试验中的普遍性.
■遵循系统评价和荟萃分析指南的首选报告项目,我们在五个不同的数据库中进行了优化搜索.删除重复项后,65项研究纳入我们的综述。
■研究早在2016年就有许多不同的来源国家。PSMAPET的参考标准有差异,有些使用活检标本或手术标本,在某些情况下,两者的结合。当研究选择有临床意义的PCa的组织学定义时,注意到类似的不一致。虽然有些人完全省略了他们的定义。执行PSMAPET的最重要的变化是放射性示踪剂类型,剂量,注射后的采集时间,和PET相机正在使用。注意到PSMAPET的报告存在重大差异,在定义什么是前列腺内阳性病变方面没有一致性。在65项研究中,使用了四种不同的定义。
■本系统综述强调了在原发性PCa诊断背景下获得和进行PSMAPET研究的相当大的差异。鉴于PSMAPET的执行和报告方式存在差异,它质疑从一个中心到另一个中心的研究。PSMAPET的标准化是必需的,以使其成为PCa诊断中一贯有用且可重复的方式。
■前列腺特异性膜抗原(PSMA)正电子发射断层扫描(PET)正在用于前列腺癌(PCa)的分期和定位;然而,在执行和报告PSMAPET方面存在显著差异。PSMAPET的标准化对于PCa的诊断是一致有用和可再现的。
UNASSIGNED: Prostate cancer (PCa) remains one of the leading causes of cancer-related deaths in men worldwide. Men at risk are typically offered multiparametric magnetic resonance imaging and, if suspicious, a targeted biopsy. However, false-negative rates of magnetic resonance imaging are consistently 18%; therefore, there is growing interest in improving the diagnostic performance of imaging through novel technologies. Prostate-specific membrane antigen (PSMA) positron emission tomography (PET) is being utilised for PCa staging and, more recently, for intraprostatic tumour localisation. However, significant variability has been observed in how PSMA PET is performed and reported.
UNASSIGNED: In this review, we aim to evaluate how pervasive this variability is in trials investigating the performance of PSMA PET in primary PCa workup.
UNASSIGNED: Following the Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines, we performed an optimal search in five different databases. After removing duplicates, 65 studies were included in our review.
UNASSIGNED: Studies dated back as early as 2016, with numerous different source countries. There was variation in the reference standard for PSMA PET, with some using biopsy specimens or surgical specimens, and in some cases, a combination of the two. Similar inconsistencies were noted when studies selected histological definitions of clinically significant PCa, while some omitted their definition altogether. The most significant variations in performing PSMA PET were the radiotracer type, dose, acquisition time after injection, and the PET camera being utilised. Substantial variation in the reporting of PSMA PET was noted, with no consistency in defining what constitutes a positive intraprostatic lesion. Across 65 studies, four different definitions were used.
UNASSIGNED: This systematic review has highlighted considerable variation in obtaining and performing a PSMA PET study in the context of primary PCa diagnosis. Given the discrepancy in how PSMA PET was performed and reported, it questions the homogony of studies from centre to centre. Standardisation of PSMA PET is required for this to become a consistently useful and reproducible modality in the diagnosis of PCa.
UNASSIGNED: Prostate-specific membrane antigen (PSMA) positron emission tomography (PET) is being utilised for staging and localisation of prostate cancer (PCa); however, there is significant variability in performing and reporting PSMA PET. Standardisation of PSMA PET is required for results to be consistently useful and reproducible for the diagnosis of PCa.